产品详情
简单介绍：
Anti-LRFN3抗体产品质量稳定，实验效果明显，货期快，价格优惠，欢迎垂询订购！我公司长期供应**组化抗体、WB抗体、**组化试剂盒和抗体试验所需全部相关试剂、荧光标记抗体、单克隆抗体、多克隆抗体、各种标记的二抗IgG/IgM/IgD/IgA等科研实验抗体。Anti-LRFN3抗体用于**组化实验,WB实验,相应的标记抗体有HRP标记抗体,FITC标记,BIO等。
详情介绍：
Rabbit Anti-LRFN3
Cat. Number:
Anti-LRFN3抗体KL-11088R
Quantity size:
0.2ml
Concentration:
1mg/ml Buffer = 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
Background:
LRFN3 is a 628 amino acid single-pass type I membrane protein that belongs to the LRFN family. Containing seven LRR (leucine-rich) repeats, LRFN3 also contains one fibronectin type-III domain, one Ig-like (immunoglobulin-like) domain, one LRRCT domain and one LRRNT domain. As a cell adhesion molecule that Anti-LRFN3抗体mediates homophilic cell-cell adhesion in a Ca2+-independent manner, LRFN3 promotes neurite outgrowth in hippocampal neurons. LRFN3 forms homomeric complexes across cell junctions (between adjacent cells), and can form heteromeric complexes with LRFN1, LRFN2, LRFN4 and LRFN5. The gene that encodes LRFN3 consists of more than 8,000 bases and maps to human chromosome 19q13.12.
Also known as:
SALM4; Fibronectin type II immunoglobulin and leucine rich repeat domains 1; Fibronectin type II, immunoglobulin and leucine richAnti-LRFN3抗体 repeat domains 1; FIGLER1; Leucine rich repeat and fibronectin type III domain containing 3; Leucine-rich repeat and fibronectin type-III domain-containing protein 3; Lrfn3; LRFN3_HUMAN; Synaptic adhesion-like molecule 4.
Specificity:
●
Rabbit Polyclonal IgG, affinity purified by Protein A.
●
Reacts with: Human, Mouse, Rat, Pig, Cow, Horse, Sheep, .
●
Immunogen: KLH conjugated synthetic peptide derived from human LRFN3/SA.
●
Predicted Molecular Weight: Anti-LRFN3抗体65kDa.
Storage:
Shipped at 4℃, Store at -20℃ (Avoid repeated freeze/thaw cycles).
Application:
WB=1:100-500 ELISA=1:500-1000 IHC-P=1:100-500 IHC-F=1:100-500 ICC=1:100-500 IF=1:100-500
Not yet tested in other applications. Anti-LRFN3抗体
Optimal working dilutions must be determined by the end user.
Not yet tested in other applications. Anti-LRFN3抗体
Optimal working dilutions must be determined by the end user.
